Biology and Clinical Relevance of the Micropthalmia Family of Transcription Factors in Human Cancer
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Members of the micropthalmia (MiT) family of transcription factors (MITF, TFE3, TFEB, and TFEC) are physiologic regulators of cell growth, differentiation, and survival in several tissue types. Because their dysregulation can lead to melanoma, renal cell carcinoma, and some sarcomas, understanding why these genes are co-opted in carcinogenesis may be of general utility. Here we describe the structure of the MiT family of proteins, the ways in which they are aberrantly activated, and the molecular mechanisms by which they promote oncogenesis. We discuss how meaningful understanding of these mechanisms can be used to elucidate the oncogenic process. Because the expression of these proteins is essential for initiating and maintaining the oncogenic state in some cancer types, we propose ways that they can be exploited to prevent, diagnose, and rationally treat these malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Gene Network Regulating Lysosomal Biogenesis and Function
Sardiello, M., Palmieri, M., di Ronza, A., Medina, D. L., Valenza, M., Gennarino, V. A., Di Malta, C., Donaudy, F., Embrione, V., Polishchuk, R. S., et al. (2009) · Science · doi:10.1126/science.1174447 · Cited by 2,543 · cited 4×
“In a subtype of renal cell carcinomas called translocation-associated renal carcinomas, translocation of the region of the X chromosome containing TFE3 leads to the fusion of the amino-terminal portions of transcription factor E3 (TFE3) with any of several fusion partners, including PRCC, NONO, SFPQ, and CLTC (Fig 3).…”
BackgroundInfluentialBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160 · cited 1×
“MITF may also promote oncogenesis via suppression of cellular senescence, a process that prevents transformation of precancerous lesions, including melanocytic nevi.(65) MITF directly induces the expression of the transcription factor TBX2, which in turn blocks senescence by suppressing the expression of CDKN1A and CD…”
BackgroundPrinciples of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548 · cited 5×
“In the melanocytic lineage, MITF may be a determinant of survival after irradiation,(87) but its association with resistance to chemotherapy is controversial.(28,88) In the largest published study, MITF amplification was found to be a prognostic marker for survival but not a predictive marker for chemosensitivity or c…”
BackgroundInfluentialSelf-citationTranscription factors as targets for cancer therapy
Darnell, J. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc906 · Cited by 1,194 · cited 1×
“Over the ensuing years, many other dysregulated transcription factors have been implicated in human cancers, including breast, colon, lung, and hematopoietic cancers.(3) Recent research has implicated a family of transcription factors known as the micropthalmia (MiT) -related transcription factors in melanoma, sarcoma…”
BackgroundMITF: master regulator of melanocyte development and melanoma oncogene
Levy, C., Khaled, M., & Fisher, D. E. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.008 · Cited by 1,169 · cited 1×
“As predicted based on its expression pattern in the melanocytic lineage, MITF binds to and activates the expression of a large repertoire of enzymes essential for melanocyte differentiation and melanin production, including tyrosinase, DCT, and TYRP1, leading to its designation as the master regulator of melanocyte de…”
BackgroundSelf-citationBoni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742 · cited 12×
“Homodimerization and heterodimerization with other members of the MiT family can occur in vitro,4 but it is unclear if the latter occurs in vivo.5 Other members of the extended bHLH-Zip family such as C-MYC are unable to bind to MiT family members.4 Because of their sequence homology, all MiT family members bind to id…”
BackgroundInfluentialSelf-citationHemesath, T. J., Steingrímsson, E., McGill, G., Hansen, M. J., Vaught, J., Hodgkinson, C. A., Arnheiter, H., Copeland, N. G., Jenkins, N. A., & Fisher, D. E. (1994) · Genes & Development · doi:10.1101/gad.8.22.2770 · Cited by 673
Self-citationMitf regulation of Dia1 controls melanoma proliferation and invasiveness
Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K. S., Testori, A., Larue, L., & Goding, C. R. (2006) · Genes & Development · doi:10.1101/gad.406406 · Cited by 608
Jacobs, J. J. L., Keblusek, P., Robanus-Maandag, E., Kristel, P., Lingbeek, M., Nederlof, P. M., van Welsem, T., van de Vijver, M. J., Koh, E. Y., Daley, G. Q., et al. (2000) · Nature Genetics · doi:10.1038/81583 · Cited by 368 · cited 2×
“MITF directly induces the expression of the transcription factor TBX2, which in turn blocks senescence by suppressing the expression of CDKN1A and CDKN2A.(66,67)”
Background
Cited by
Roczniak-Ferguson, A., Petit, C. S., Froehlich, F., Qian, S., Ky, J., Angarola, B., Walther, T. C., & Ferguson, S. M. (2012) · Science Signaling · doi:10.1126/scisignal.2002790 · Cited by 1,366
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G. C., Frederick, D. T., Hurley, A. D., Nellore, A., Kung, A. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.003 · Cited by 818
“, 2011), whereas activation of MITF expression in normal melanocytes typically induces differentiation, which likely antagonizes tumorigenesis (D’Orazio et al., 2006; Carreira et al., 2006; Haq and Fisher, 2011).”
InfluentialSelf-citationTranscriptional control of autophagy-lysosome function drives pancreatic cancer metabolism
Perera, R. M., Stoykova, S., Nicolay, B. N., Ross, K. N., Fitamant, J., Boukhali, M., Lengrand, J., Deshpande, V., Selig, M. K., Ferrone, C. R., et al. (2015) · Nature · doi:10.1038/nature14587 · Cited by 799
The Lysosome as a Regulatory Hub
Perera, R. M., & Zoncu, R. (2016) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-111315-125125 · Cited by 660
Puertollano, R., Ferguson, S. M., Brugarolas, J., & Ballabio, A. (2018) · The EMBO Journal · doi:10.15252/embj.201798804 · Cited by 531
TFEB and TFE3: Linking Lysosomes to Cellular Adaptation to Stress
Raben, N., & Puertollano, R. (2016) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-111315-125407 · Cited by 437
Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB
Polito, V. A., Li, H., Martini‐Stoica, H., Wang, B., Yang, L., Xu, Y., Swartzlander, D. B., Palmieri, M., di Ronza, A., Lee, V. M., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201303671 · Cited by 368
Spectrum of diverse genomic alterations define non–clear cell renal carcinoma subtypes
Durinck, S., Stawiski, E. W., Pavía-Jiménez, A., Modrusan, Z., Kapur, P., Jaiswal, B. S., Zhang, N., Toffessi-Tcheuyap, V., Nguyen, T. T., Pahuja, K. B., et al. (2015) · Nature Genetics · doi:10.1038/ng.3146 · Cited by 357
Recruitment of folliculin to lysosomes supports the amino acid–dependent activation of Rag GTPases
Petit, C. S., Roczniak-Ferguson, A., & Ferguson, S. M. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201307084 · Cited by 355
“However, independent of any mutation affecting canonical components of the mTORC1 signaling pathway, the overexpression of MiT-TFE transcription factors due to chromosomal translocations is sufficient to cause renal carcinoma in humans (Haq and Fisher, 2011; Linehan, 2012).”
BackgroundMITF in melanoma: mechanisms behind its expression and activity
Hartman, M. L., & Czyz, M. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1791-0 · Cited by 320
Flucke, U., Vogels, R. J., de Saint Aubain Somerhausen, N., Creytens, D. H., Riedl, R. G., van Gorp, J. M., Milne, A. N., Huysentruyt, C. J., Verdijk, M. A., van Asseldonk, M. M., et al. (2014) · Diagnostic Pathology · doi:10.1186/1746-1596-9-131 · Cited by 269
Transcriptional Regulation of Autophagy: Mechanisms and Diseases
Di Malta, C., Cinque, L., & Settembre, C. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00114 · Cited by 255
MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells
Ploper, D., Taelman, V. F., Robert, L., Perez, B. S., Titz, B., Chen, H.-W., Graeber, T. G., von Euw, E., Ribas, A., & De Robertis, E. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424576112 · Cited by 228
Marchand, B., Arsenault, D., Raymond-Fleury, A., Boisvert, F.-M., & Boucher, M.-J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.616714 · Cited by 168
“oncogenic activity although the mechanisms involved remain elusive (60).”
BackgroundTorra, A., Parent, A., Cuadros, T., Rodríguez-Galván, B., Ruiz-Bronchal, E., Ballabio, A., Bortolozzi, A., Vila, M., & Bové, J. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.022 · Cited by 88
Du, K., Chen, H., Pan, Z., Zhao, M., Cheng, S., Luo, Y., Zhang, W., & Li, D. (2025) · eLife · doi:10.7554/elife.103137 · Cited by 13
Metadata
- Authors
- Haq, R., & Fisher, D. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-09-01
- Volume
- 29
- Issue
- 25
- Pages
- 3474-3482
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2109478314
- Cited by
- 146
- References
- 12
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.